Unusual paradoxical embolic stroke in a patient with persistent left superior vena cava

Tae-Hun KWON; Kang-Un CHOI; Byung-Jun KIM; Jae-Ho CHO; Jae-Young LEE; Kyu-Hwan PARK; Sang-Hee LEE; Jang-Won SON.
Yeungnam University Journal of Medicine ; : 118-121, 2015.
Artículo en Ko | WPRIM | ID: wpr-213784

Documentos relacionados

  1. Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.
  2. Binding Interactions of Ergotamine and Dihydroergotamine to 5-Hydroxytryptamine Receptor 1B (5-HT<sub>1b</sub>) Using Molecular Dynamics Simulations and Dynamic Network Analysis.
  3. STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD<sup>®</sup> ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients.
  4. Drug Repurposing to Inhibit Histamine <i>N</i>-Methyl Transferase.
  5. Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults.
  6. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
  7. Dihydroergotamine (DHE) - Then and Now: A Narrative Review.
  8. Dihydroergotamine extravasation: prolonged arterial vasospasm requiring medical and surgical treatment.
  9. A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults.
  10. Dihydroergotamine infusion for pediatric refractory headache: A retrospective chart review.